{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:54:59Z","timestamp":1786121699303,"version":"build-2736575974"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014173","name":"Independence Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014173","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.euf.2026.06.020","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T20:28:46Z","timestamp":1784752126000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["BCG at Home: A First-in-kind Trial of Home-based Intravesical Bacillus Calmette-Gu\u00e9rin Delivery for High-risk Non\u2013muscle-invasive Bladder Cancer"],"prefix":"10.1016","author":[{"given":"Daniel J.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheyenne","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Soefje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Northern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinah","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Radovanovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Cappozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aquilla","family":"Obare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Stambakio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Guzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trinity J.","family":"Bivalacqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2026.06.020_b0005","doi-asserted-by":"crossref","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","article-title":"NCCN Guidelines\u00ae insights: bladder cancer, version 3.2024","volume":"22","author":"Flaig","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.euf.2026.06.020_b0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JU.0000000000003981","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO guideline (2017; amended 2020, 2024)","volume":"212","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2026.06.020_b0015","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)-A summary of the 2024 guidelines update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.06.020_b0020","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1056\/NEJM199110243251703","article-title":"A randomized trial of intravesical doxorubicin and immunotherapy with Bacille Calmette-Gu\u00e9rin for transitional-cell carcinoma of the bladder","volume":"325","author":"Lamm","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2026.06.020_b0025","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2026.06.020_b0030","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.euf.2025.04.033","article-title":"Long-term oncological outcomes for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin (BCG): A comparative analysis of adequate versus inadequate BCG treatment","volume":"12","author":"Scilipoti","year":"2026","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2026.06.020_b0035","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.urolonc.2020.06.013","article-title":"Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: a systematic review","volume":"38","author":"Mori","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2026.06.020_b0040","doi-asserted-by":"crossref","first-page":"109","DOI":"10.36469\/jheor.2024.124208","article-title":"Adherence to first-line intravesical bacillus Calmette-Gu\u00e9rin therapy in the context of guideline recommendations for US patients with high-risk non-muscle invasive bladder cancer","volume":"11","author":"Gaylis","year":"2024","journal-title":"J Health Econ Outcomes Res"},{"key":"10.1016\/j.euf.2026.06.020_b0045","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1002\/cncr.26198","article-title":"Compliance with guidelines for patients with bladder cancer: variation in the delivery of care","volume":"117","author":"Chamie","year":"2011","journal-title":"Cancer."},{"key":"10.1016\/j.euf.2026.06.020_b0050","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/cncr.26402","article-title":"Quality of care in patients with bladder cancer: a case report?","volume":"118","author":"Chamie","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2026.06.020_b0055","doi-asserted-by":"crossref","DOI":"10.1002\/bco2.70025","article-title":"Outcomes in BCG failure: outcome from a single centre UK experience","volume":"6","author":"Day","year":"2025","journal-title":"BJUI Compass"},{"key":"10.1016\/j.euf.2026.06.020_b0060","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2014.01.006","article-title":"The economics of bladder cancer: costs and considerations of caring for this disease","volume":"66","author":"Svatek","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.06.020_b0065","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.urology.2019.06.021","article-title":"Compliance with American Urological Association guidelines for nonmuscle invasive bladder cancer remains poor: assessing factors associated with noncompliance and survival in a rural state","volume":"132","author":"Tobert","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.euf.2026.06.020_b0070","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/ijun.12236","article-title":"Withdrawing from treatment for Bladder cancer: patient experiences of BCG installations","volume":"14","author":"Alcorn","year":"2020","journal-title":"Int J Urol Nurs"},{"key":"10.1016\/j.euf.2026.06.020_b0075","doi-asserted-by":"crossref","first-page":"70.e1","DOI":"10.1016\/j.urolonc.2024.01.013","article-title":"Patient experience and unmet needs in high-risk nonmuscle-invasive bladder cancer: insights from qualitative interviews and a cross-sectional survey","volume":"42","author":"Kopenhafer","year":"2024","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2026.06.020_b0080","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1136\/bmj.322.7290.826","article-title":"Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trial","volume":"322","author":"Borras","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.euf.2026.06.020_b0085","article-title":"Accelerating the delivery of cancer care at home during the Covid-19 pandemic","volume":"1","author":"Laughlin","year":"2020","journal-title":"Catal Non-Issue Content"},{"key":"10.1016\/j.euf.2026.06.020_b0090","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/00004045-199109000-00012","article-title":"Home bacillus Calmette-Guerin therapy for the treatment of superficial bladder cancer","volume":"9","author":"Giglione","year":"1991","journal-title":"Home Healthc Nurse"},{"key":"10.1016\/j.euf.2026.06.020_b0095","first-page":"4","article-title":"DH praise for home chemotherapy patient services may lead to pilot projects across England and Wales","volume":"5","author":"Harrison","year":"2006","journal-title":"Cancer Nurs Pract"},{"key":"10.1016\/j.euf.2026.06.020_b0100","unstructured":"Intravesical administration of therapeutic medication for the treatment of bladder cancer. Jointly developed with the Society of Urologic Nurses and Associates (SUNA). American Urological Association, https:\/\/www.auanet.org\/about-us\/aua-statements\/intravesical-administration-of-therapeutic-medication."},{"key":"10.1016\/j.euf.2026.06.020_b0105","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.euo.2020.03.004","article-title":"Bacillus Calmette-Gu\u00e9rin retains clinically relevant viability for up to 72 hours after reconstitution: potential implications for clinical practice in times of shortage","volume":"4","author":"Brooks","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2026.06.020_b0110","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/ajhp\/zxaa339","article-title":"Development of an innovative delivery system for bacillus Calmette-Gu\u00e9rin bladder administration","volume":"78","author":"Szewczyk","year":"2021","journal-title":"Am J Health Syst Pharm."},{"key":"10.1016\/j.euf.2026.06.020_b0115","doi-asserted-by":"crossref","DOI":"10.1177\/20503121241230449","article-title":"Evaluating drug stability and sterility in single-dose vials when accessed with a closed system transfer device","volume":"12","author":"Hopkins","year":"2024","journal-title":"Sage Open Med"},{"key":"10.1016\/j.euf.2026.06.020_b0120","unstructured":"USP compounding standards and beyond-use dates (BUDs). The United States Pharmacopeial Convention, https:\/\/www.usp.org\/sites\/default\/files\/usp\/document\/our-work\/compounding\/usp-bud-factsheet.pdf."},{"key":"10.1016\/j.euf.2026.06.020_b0125","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1111\/j.1464-410X.2011.10735.x","article-title":"Screening urine analysis before Bacille Calmette-Gu\u00e9rin instillation does not reduce the rate of infectious complications","volume":"109","author":"Zhao","year":"2012","journal-title":"BJU Int"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926001161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926001161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T05:55:52Z","timestamp":1786082152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456926001161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":25,"alternative-id":["S2405456926001161"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2026.06.020","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BCG at Home: A First-in-kind Trial of Home-based Intravesical Bacillus Calmette-Gu\u00e9rin Delivery for High-risk Non\u2013muscle-invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2026.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}